Navigation Links
Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round
Date:2/24/2009

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised $7.1 million in a Series A financing co-led by InterWest Partners and Vivo Ventures. The two firms were instrumental in the formation of the company and recruitment of its team and are represented on the board of directors by general partners Nina Kjellson and Dr. Edgar Engelman, respectively. The funding will advance the company's lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.

Eiger is led by President and Chief Executive Officer David Cory, RPh, MBA, whose background spans over 20 years in large pharma, biotechnology, and specialty pharma with an established track record of commercial success, financial transactions, business development, and management experience. "We believe that disrupting the normal function of NS4B and NS5A proteins will lead to uniquely effective hepatitis C treatments," said David Cory, President and CEO of Eiger. "Our mission is to advance these novel small molecules into the clinic rapidly for the benefit of patients."

Eiger was founded on research conducted by Stanford professor Jeffrey Glenn, MD, PhD, whose recent research focuses on specific regions of HCV proteins NS4B and NS5A required for viral replication. "The unmet medical need in HCV treatment is significant," said Dr. Glenn. "Developing small molecule drugs and drug combinations against new HCV targets could change the HCV treatment paradigm and combat the emergence of drug resistance to new HCV polymerase and protease inhibitors." Dr. Glenn is Associate Professor of Medicine, Gastroenterology & Hepatology, Stanford University and Director of the Center for Hepatitis and Liver Tissue Engineering; he wi
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
3. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
4. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
5. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. XTL Biopharmaceuticals Implements Restructuring Plan
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... 19, 2011 New Report Added in ... to 2020 - Programmable Logic Devices (PLD) and Application Specific ...   Published by  GBI Research . ... 2020 Programmable Logic Devices (PLD) and Application Specific Standard Product ...
... about how certain kinds of bacteria make energy and synthesize ... team of scientists led by Donald Bryant, the Ernest C. ... research professor in the Department of Chemistry and Biochemistry at ... the journal Science on 16 December 2011, is ...
... The efficiency of conventional solar cells could be ... of solar energy conversion led by chemist Xiaoyang Zhu ... and his team have discovered that it,s possible to ... of sunlight using an organic plastic semiconductor material. ...
Cached Biology Technology:ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 2Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 3Discovery of a 'dark state' could mean a brighter future for solar energy 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... On Monday, August 17th at 1:30PM in Hensill Hall 113, ... AAAS in San Francisco will get to learn about the ... minds in the field. The symposium is called Good ... the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As science ...
... another piece to the mounting body of evidence that ... arrest, "passive ventilation" significantly increases survival rates, compared to ... in an online edition of Annals of Emergency Medicine, ... cardiac arrest outside a hospital setting and were resuscitated ...
... 12, 2009) Research published online in the journal ... are associated with a 2.5-fold reduction in risk for neural ... brain and spinal cord, and the two most common NTDs ... Disease Control (CDC), an estimated 3,000 pregnancies in the U.S. ...
Cached Biology News:Science communication to take the stage at annual AAAS meeting in San Francisco 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3
... pp65 Antigenemia Immunofluorescence Assay (IFA) is intended ... protein pp65 of CMV in isolated peripheral ... Erythrocyte Lysis Buffer - (Catalog ... of buffered ammonium chloride. (NH4CL) Fixation ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... samples for freezing point determinations. Includes built-in printer, keypad, and software for ... RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: